IMMUNOREACT 7: Regular aspirin use is associated with immune surveillance activation in colorectal cancer.
CD8
CD80
aspirin
colorectal cancer
nodal metastasis
tumor infiltrating lymphocytes
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
revised:
19
01
2024
received:
06
09
2023
accepted:
13
02
2024
medline:
22
4
2024
pubmed:
22
4
2024
entrez:
22
4
2024
Statut:
aheadofprint
Résumé
Long-term daily use of aspirin reduces incidence and mortality due to colorectal cancer (CRC). This study aimed to analyze the effect of aspirin on the tumor microenvironment, systemic immunity, and on the healthy mucosa surrounding cancer. Patients with a diagnosis of CRC operated on from 2015 to 2019 were retrospectively analyzed (METACCRE cohort). Expression of mRNA of immune surveillance-related genes (PD-L1, CD80, CD86, HLA I, and HLA II) in CRC primary cells treated with aspirin were extracted from Gene Expression Omnibus-deposited public database (GSE76583). The experiment was replicated in cell lines. The mucosal immune microenvironment of a subgroup of patients participating in the IMMUNOREACT1 (ClinicalTrials.gov NCT04915326) project was analyzed with immunohistochemistry and flow cytometry. In the METACCRE Cohort, 12% of 238 patients analyzed were aspirin users. Nodal metastasis was significantly less frequent (p = .008) and tumor-infiltrating lymphocyte infiltration was higher (p = .02) among aspirin users. In the CRC primary cells and selected cell lines, CD80 mRNA expression was increased following aspirin treatment (p = .001). In the healthy mucosa surrounding rectal cancer, the ratio of CD8/CD3 and epithelial cells expressing CD80 was higher in aspirin users (p = .027 and p = .034, respectively). These data suggested that regular aspirin use may have an active role in enhancing immunosurveillance against CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Long-term daily use of aspirin reduces incidence and mortality due to colorectal cancer (CRC). This study aimed to analyze the effect of aspirin on the tumor microenvironment, systemic immunity, and on the healthy mucosa surrounding cancer.
METHODS
METHODS
Patients with a diagnosis of CRC operated on from 2015 to 2019 were retrospectively analyzed (METACCRE cohort). Expression of mRNA of immune surveillance-related genes (PD-L1, CD80, CD86, HLA I, and HLA II) in CRC primary cells treated with aspirin were extracted from Gene Expression Omnibus-deposited public database (GSE76583). The experiment was replicated in cell lines. The mucosal immune microenvironment of a subgroup of patients participating in the IMMUNOREACT1 (ClinicalTrials.gov NCT04915326) project was analyzed with immunohistochemistry and flow cytometry.
RESULTS
RESULTS
In the METACCRE Cohort, 12% of 238 patients analyzed were aspirin users. Nodal metastasis was significantly less frequent (p = .008) and tumor-infiltrating lymphocyte infiltration was higher (p = .02) among aspirin users. In the CRC primary cells and selected cell lines, CD80 mRNA expression was increased following aspirin treatment (p = .001). In the healthy mucosa surrounding rectal cancer, the ratio of CD8/CD3 and epithelial cells expressing CD80 was higher in aspirin users (p = .027 and p = .034, respectively).
CONCLUSIONS
CONCLUSIONS
These data suggested that regular aspirin use may have an active role in enhancing immunosurveillance against CRC.
Banques de données
ClinicalTrials.gov
['NCT04915326']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro; Investigator Grant
ID : 2019 Id.23381
Informations de copyright
© 2024 American Cancer Society.
Références
Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005;365(9454):153‐165. doi:10.1016/s0140‐6736(05)17706‐x
Wang X, Chan AT, Slattery ML, et al. Influence of smoking, body mass index and other factors on the preventive effect of nonsteroidal anti‐inflammatory drugs on colorectal cancer risk. Cancer Res. 2018;78(16):4790‐4799. doi:10.1158/0008‐5472.can‐18‐0326
Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta‐analysis through 2019. Ann Oncol. 2020;31(5):558‐568. doi:10.1016/j.annonc.2020.02.012
Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor‐targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A. 2012;109(20):7841‐7846. doi:10.1073/pnas.1118296109
Rothwell PM, Wilson M, Elwin CE, et al. Long‐term effect of aspirin on colorectal cancer incidence and mortality: 20‐year follow‐up of five randomized trials. Lancet. 2010;376(9754):1741‐1750. doi:10.1016/s0140‐6736(10)61543‐7
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomized controlled trials. Lancet. 2012;379(9826):1591‐1601. doi:10.1016/s0140‐6736(12)60209‐8
Flossmann E, Rothwell PM. British Doctors Aspirin Trial and the UK‐TIA Aspirin Trial. Effect of aspirin on long‐term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet. 2007;369(9573):1603‐1613. doi:10.1016/s0140‐6736(07)60747‐8
Lin J‐L, Zheng CH, et al. Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta‐analysis. BMC Cancer. 2020;20(1):638. doi:10.1186/s12885‐020‐07117‐4
Hua X, Phipps AI, Burnett‐Hartman AN, et al. Timing of aspirin and other nonsteroidal anti‐inflammatory drug use among patients with colorectal cancer about tumor markers and survival. J Clin Oncol. 2017;35(24):2806‐2813. doi:10.1200/jco.2017.72.3569
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134(1):21‐28. doi:10.1053/j.gastro.2007.09.035
Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649‐658. doi:10.1001/jama.2009.1112
Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet‐tumor‐cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 1973;11(3):704‐718. doi:10.1002/ijc.2910110322
Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemostasis. 2011;9(2):237‐249. doi:10.1111/j.1538‐7836.2010.04131.x
Gay LJ, Felding‐Habermann B. Contribution of platelets to tumor metastasis. Nat Rev Cancer. 2011;11(2):123‐134. doi:10.1038/nrc3004
Zhou X. SOX7 is involved in aspirin‐mediated growth inhibition of human colorectal cancer cells. WJG. 2011;17(44):4922. doi:10.3748/wjg.v17.i44.4922
Wang Y, Du C, Zhang N, et al. TGF‐β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis. Oncol Lett. 2018;15:5903‐5909. doi:10.3892/ol.2018.8047
Ohnishi S, Hiramoto K, Ma N, Kawanishi S. Chemoprevention by aspirin against inflammation‐related colorectal cancer in mice. J Clin Biochem Nutr. 2021;69(3):265‐271. doi:10.3164/jcbn.20‐189
Guo Y, Liu Y, Zhang C, et al. The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane‐ and dextran sulfate sodium‐treated CF‐1 mice. Carcinogenesis. 2016;37(6):616‐624. doi:10.1093/carcin/bgw042
Cao Y, Nishihara R, Qian ZR, et al. Regular aspirin use is associates with a lower risk of colorectal cancers with low numbers of tumor‐infiltrating lymphocytes. Gastroenterology. 2016;151(5):879‐892. doi:10.1053/j.gastro.2016.07.030
Angriman I, Fassan M, Nacci C, et al. Metachronous colorectal cancer has a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions. Surgery. 2022;171(6):1605‐1611. doi:10.1016/j.surg.2021.12.005
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471‐1474. doi:10.1245/s10434‐010‐0985‐4
Cappellesso R, Fassan M, Hanspeter E, et al. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. Hum Pathol. 2015;46(5):665‐672. doi:10.1016/j.humpath.2015.02.007
Remo A, Fassan M, Lanza G. Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal. Pathologica. 2016;108:104‐109.
Bocker T, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. 1997;57:4739‐4743.
Simbolo M, Gottardi M, Corbo V, et al. DNA qualification workflow for next‐generation sequencing of histopathological samples. PLoS One. 2013;8(6):e62692. doi:10.1371/journal.pone.0062692
Guo H, Liu J, Ben Q, et al. The aspirin‐induced long non‐coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. Genome Biol. 2016;17(1):24. doi:10.1186/s13059‐016‐0892‐5
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2022. https://www.R‐project.org/
Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol. 2015;30(1):5‐18. doi:10.1007/s10654‐014‐9971‐7
Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer about the expression of COX‐2. N Engl J Med. 2007;356(21):2131‐2142. doi:10.1056/nejmoa067208
Ranger GS. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 2014;34:6277‐6282.
Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16(3):173‐186. doi:10.1038/nrc.2016.4
Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. Int J Epidemiol. 2007;36(5):951‐957. doi:10.1093/ije/dym193
Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Low‐dose aspirin use and cancer characteristics: a population‐based cohort study. Br J Cancer. 2013;109(7):1921‐1925. doi:10.1038/bjc.2013.411
Giorli G, Rouette J, Yin H, et al. Prediagnostic use of low‐dose aspirin and risk of incident metastasis and all‐cause mortality among patients with colorectal cancer. Br J Clin Pharmacol. 2020;86(11):2266‐2273. doi:10.1111/bcp.14329
Khorana AA. Malignancy, thrombosis, and Trousseau: the case for an eponym. J Thromb Haemostasis. 2003;1(12):2463‐2465. doi:10.1111/j.1538‐7836.2003.00501.x
Ying J, Zhou H, Liu P, et al. Aspirin inhibits the metastasis of colon cancer cells by inhibiting the expression of toll‐like receptor 4. Cell Biosci. 2018;8:1. doi:10.1186/s13578‐017‐0198‐7
Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase‐dependent tumor growth through evasion of immunity. Cell. 2015 Sep 10;162(6):1257‐1270. doi:10.1016/j.cell.2015.08.015
Haram A, Boland MR, Kelly ME, Bolger JC, Waldron RM, Kerin MJ. The prognostic value of the neutrophil‐to‐lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol. 2017;115(4):470‐479. doi:10.1002/jso.24523
Vannitamby A, Saad MI, Aloe C, et al. Aspirin‐triggered Resolvin D1 reduces proliferation and the neutrophil to lymphocyte ratio in a mutant KRAS‐driven lung adenocarcinoma model. Cancers. 2021;13:3224. doi:10.3390/cancers13133224
Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM, Rehman MU. Aspirin and immune system. Int Immunopharm. 2012;12(1):10‐20. doi:10.1016/j.intimp.2011.11.021
Soon SS, Chia WK, Chan MS, et al. Cost‐effectiveness of aspirin adjuvant therapy in early‐stage colorectal cancer in older patients. PLoS One. 2014;9:e107866. doi:10.1371/journal.pone.0107866
Hackstein H, Morelli AE, Larregina AT, et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol. 2001;166(12):7053‐7062. doi:10.4049/jimmunol.166.12.7053
Matasic R, Dietz AB, Vuk‐Pavlovic S. Cyclooxygenase‐independent inhibition of dendritic cell maturation by aspirin. Immunology. 2000;101(1):53‐60. doi:10.1046/j.1365‐2567.2000.00065.x
Wallinger S, Dietmaier W, Beyser K, et al. Aspirin supprimiert Mikrosatelliten‐Instabilität [Aspirin suppresses microsatellite instability]. Verh Dtsch Ges Pathol. 1999;83:240‐246.
Scarpa M, Marchiori C, Scarpa M, Castagliuolo I. CD80 expression is upregulated by TP53 activation in human cancer epithelial cells. OncoImmunology. 2021;10(1):1907912. doi:10.1080/2162402x.2021.1907912
Marchiori C, Scarpa M, Kotsafti A, et al. Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions, and its expression is increased by oxidative stress through STAT3 in colon cancer cells. J Exp Clin Cancer Res. 2019;38(1):190. doi:10.1186/s13046‐019‐1205‐0
Scarpa M, Brun P, et al. CD80‐CD28 signaling controls the progression of inflammatory colorectal carcinogenesis. Oncotarget. 2015;6(24):20058‐20069. doi:10.18632/oncotarget.2780
Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Non‐steroidal anti‐inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40(5):619‐622. doi:10.1136/gut.40.5.619
Meshkinpour H, Hollander D, Harmon D. Colonic absorption of acetylsalicylic acid in the rat. Gen Pharmacol. 1984;15(1):55‐58. doi:10.1016/0306‐3623(84)90081‐8
Hollander D, Dadufalza VD, Fairchild PA. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med. 1981 Oct;98(4):591‐598
Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008 Dec 11;359(24):2567‐2578. Erratum in: N Engl J Med. 2009 Apr 2;360(14):1470. doi:10.1056/NEJMoa0801297